A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
ABBV-011 1.0 mg/kg every 3 weeks monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated patients with relapsed/refractory SCLC. SEZ6 is a promising novel SCLC target and warrants further investigation.
Authors
- Edwin E. Jeng (ORCID: https://orcid.org/0000-0003-2824-4763)
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Noura J. Choudhury (ORCID: https://orcid.org/0000-0002-5980-4973)
- Haruyasu Murakami (ORCID: https://orcid.org/0000-0003-2416-546X)
- Susanne M. Arnold (ORCID: https://orcid.org/0000-0001-6542-9551)
- Daniel Morgensztern (ORCID: https://orcid.org/0000-0003-4349-2028)
- Anne C. Chiang (ORCID: https://orcid.org/0000-0002-2111-4694)
- Jiuhong Zha (ORCID: https://orcid.org/0000-0003-2344-474X)
- Afshin Dowlati (ORCID: https://orcid.org/0000-0003-4535-6839)
- Aparna Hegde (ORCID: https://orcid.org/0000-0001-6616-4882)
- Hiroshi Yokouchi (ORCID: https://orcid.org/0000-0001-5964-0051)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Randy Robinson (ORCID: https://orcid.org/0000-0002-9503-1111)
- Kaname Nosaki (ORCID: https://orcid.org/0000-0002-1800-9455)
- Pooja Hingorani (ORCID: https://orcid.org/0000-0002-4772-7456)
- Sonam Puri (ORCID: https://orcid.org/0000-0001-8068-5051)
- David P. Carbone (ORCID: https://orcid.org/0000-0003-3002-1921)
- Anthony W. Tolcher (ORCID: https://orcid.org/0000-0002-6322-9721)
- Song Wang (ORCID: https://orcid.org/0000-0003-1135-7518)
- Zofia Piotrowska (ORCID: https://orcid.org/0000-0002-9008-8573)
- Toshiyuki Kozuki (ORCID: https://orcid.org/0000-0001-8432-8975)
- Tianhong Li (ORCID: https://orcid.org/0000-0001-7422-3520)
- Neal Ready
- Muhammad Furqan (ORCID: https://orcid.org/0000-0003-3137-2053)
- Hiroaki Akamatsu (ORCID: https://orcid.org/0000-0001-5856-5512)
- Rafael Santana-Dávila (ORCID: https://orcid.org/0000-0001-5051-1755)
- Rui Li (ORCID: https://orcid.org/0009-0001-4383-5038)
- Eric Schaefer
Institutions
- University of Iowa (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Kentucky (US)
- Duke University (US)
- Wakayama Medical University (JP)
- University of Washington (US)
- Washington University in St. Louis (US)
- University Hospitals of Cleveland (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- New Haven Public Schools (US)
- Huntsman Cancer Institute (US)
- Markey Cancer Center (US)
- The Ohio State University Wexner Medical Center (US)
- AbbVie (United States) (US)
- University of Alabama at Birmingham (US)
- Yale University (US)
- Kettering University (US)
- Massachusetts General Hospital (US)
- Shizuoka Cancer Center (JP)
- Northwestern Memorial Hospital (US)
- Cancer Consortium (US)
- Urology San Antonio (US)
- Sarah Cannon (US)
- National Hospital Organization Hokkaido Medical Center (JP)
- Highlands Oncology Group (US)
- South Texas Accelerated Research Therapeutics (US)
- University Hospitals Seidman Cancer Center (US)
- Duke Medical Center (US)
- Tennessee Oncology (US)
- Shikoku Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Center for Cancer Research (US)
- Duke University Hospital (US)
- Sapporo National Hospital (JP)
- Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium
- The Ohio State University (US)
- Seattle University (US)
- Case Western Reserve University (US)
- University of California, Davis (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1547
- Citations
- 27
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.78
Funders
- Aptitude Health